ADVENZYMESNSEAdvanced Enzyme Technologies LimitedHighNeutral
Announced Sat, 9 May · 13:52 IST

Advanced Enzyme Technologies Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2026, recommended Final Dividend of Rs. 1.35 per equity share.

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

ADVENZYMES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.8%1-day move
₹361.75
prior close
₹378.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.4+6.0+6.9+6.6+2.8+1.2+0.8+0.1-0.1+7.7+7.5+0.2-8.7
Up moveDown movePending
AI summary

Advanced Enzyme Technologies reported strong FY26 consolidated results. Revenue grew 17% to ₹7,457.57 million (FY25: ₹6,369.10 million). Profit after tax rose ~29.6% to ₹1,736.08 million (FY25: ₹1,339.74 million). EBITDA margin expanded to ~35%. The Board recommended a final dividend of ₹1.35 per share (67.5% payout on ₹2 face value), subject to shareholder approval at the 37th AGM. An interim dividend was deliberately deferred to preserve capital for potential strategic acquisitions or corporate actions. The auditor issued an unmodified opinion with no qualifications. Exceptional items include ₹47.81 million (net) from new labour code implementation and a ₹161.39 million reversal of a lawsuit provision following a favourable US court ruling. The company allotted 49,350 equity shares under its ESOP scheme 2022.

Likely market impact

The 29.6% PAT growth and margin expansion are positive signals. The deferred interim dividend suggests the company is prioritizing capital preservation for strategic deals, which could be value-accretive for long-term shareholders.